Linear Accelerator Based Stereotactic Ablative Radiation of Orbital Malignancies

Kiran Turaka, Aruna Turaka* and Bobby N Koneru

Paramount Oncology Group, Cedar Rapids IA, USA

*Corresponding author: Aruna Turaka, Paramount Oncology Group, Cedar Rapids, Albert G. and Helen Nassif Radiation Center, Unity Point Health-St. Luke’s Hospital, 202 10th Street SE, Suite 195, Cedar Rapids IA 52403, USA, Tel: 319-861-6944; Fax: 319-861-6945; E-mail: arunaturaka@gopog.com

Received date: April 19, 2016; Accepted date: April 21, 2016; Published date: April 25, 2016

Copyright: © 2016 Turaka K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Keywords: Cyber knife radiotherapy; Gamma knife; Orbital apex tumors; Orbital tumors; Stereotactic body radiation therapy

Editorial

Orbit has a complex anatomy with multiple structures embedded in it. Primary malignant tumors of the orbit are rare. Orbital neoplasms are usually multifaceted and require an interdisciplinary approach. They occur in adults over the age of 60 years. But benign orbital conditions can occur at young age [1]. After confirming the diagnosis of orbital tumors; various treatment methods performed are either surgery, chemotherapy, hormone therapy or radiation therapy (external beam, plaque brachytherapy, proton beam therapy). Treating the tumors located in the orbital apex region with radiation therapy is always challenging with dose limits to the optic nerve, optic chiasm and retina. Each treatment modality can have different tumor responses depending on the size, type and location of the tumor. Advanced radiation treatment techniques have achieved high tumor control rate of approximately 90% with globe preservation [1,2]. Stereotactic body radiotherapy (SBRT) or stereotactic radiosurgery (SRS) is an advanced radiation delivery method in the treatment of orbital and periorbital tumors. SBRT using either Gamma knife (frame based SRS), Cyber Knife (CK; frameless fractionated image-guided radiosurgery) or linear accelerator (e.g. True Beam) delivers high dose radiation precisely to the local tumor thereby avoiding damage to the neighboring structures [3]. The orbital tumors that can treated by SBRT are orbital lymphoma, orbital apex tumors (optic nerve sheath meningioma, neurofibroma, schwannoma, optic nerve glioma), cavernous hemangiomas, orbital melanoma, orbital metastasis, basal cell carcinoma, orbital pseudotumor, and few benign orbital conditions such as Graves’ disease and chronic orbital inflammation [4-10]. Indications for using the SBRT are non-resectable or surgically complicated tumors, recurrent or previously irradiated tumors [3,4]. This procedure spares the patient of extensive orbital surgeries like orbitotomy and exenteration.

Published reports on orbital SBRT up to date were mostly using Gamma knife and CyberKnife. Recently, True beam linear accelerator (True Beam™ Radiotherapy System, Varian Medical systems, Inc.) with capabilities of delivering advanced treatments like SBRT is being adopted into practice at many community centers. Additionally, treatment times are shorter on True Beam system due to the high dose rate. Comparison of clinical outcomes, dosimetry data and the treatment times with True beam and CK are going on but there is no mature data with long-term follow up. Klingenstein et al. [4] published the outcomes data on 16 patients treated with CK-SRS for orbital metastases to doses of 16.5-25 Gy (median 18 Gy) with stable disease in 87% of cases. No serious adverse events observed in their series.

Fractionated stereotactic therapy (SFRT) to doses of 4.5-5.5 Gy in 4 sessions was found effective using GK-SRS [11] system on 23 patients with orbital apex tumors with the tumor shrinkage in 17 patients (74%) and improved visual function in 16 patients (70%). Clinical and radiographic responses were better in patients with cavernous hemangiomas. Five patients with cavernous venous hemangiomomas [12] were treated with SFRT to doses of 4000 cGy in 20 fractions (in 3 patients, 4563 cGy in 28 fractions in one patient and other with 4959 cGy in 29 fractions) and the overall tumor shrinkage was 60% without any treatment related side effects at a median follow up of 23 months. No later side effects were noted in 5 patients with optic nerve sheath meningioma [13] treated with 5040 cGy in 28 fractions using multiple non-coplanar arcs with micro multi leaf collimator and none of the patients had any evidence of disease progression.

Patients are followed up by the visual acuity, colour vision, visual fields and CT/MRI images of the orbit. SBRT is usually well tolerated by most of the patients. It helps in rapid tumor regression with good to excellent remission. It relieves the local orbital pain, preserves/ improves the visual acuity and has low morbidity. It has fewer acute and chronic complications (dry eyes, cataract) unlike the other methods such as external beam radiation therapy, plaque brachytherapy or proton beam therapy (keratitis, neovascular glaucoma, radiation optic neuropathy, retinopathy, maculopathy, vitreous hemorrhage or choriorretinal atrophy) [4-10].

SBRT is a safe and efficacious method to treat orbital tumors. This advanced technique using CK, GK or True Beam system gives excellent success especially in tumors involving the optic apparatus with little toxicity and less morbidity.

References


